Search Results

Lenalidomide

Lenalidomide is FDA approved to treat patients with:

Myeloma Awareness Month-Research Highlight: Changing the Landscape of Treatment for Multiple Myeloma (Part 2)

Myeloma Overview

We provide education and outreach programs nationwide to increase awareness of myeloma and to improve all patients’ ability to access treatment and other resources.  We are in the process of updating and enhancing our Myeloma Link webpage to provide you with more information about these programs.

A phase 1 study of CB-011, a CRISPR-edited allogeneic CAR-T targeting BCMA, in patients with multiple myeloma

In February 2021, LLS made an equity investment in Caribou Biosciences to support "A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma."  Caribou is a leading clinical-stage biotechnology company, co-founded by CRISPR pioneer and Nobel Prize winner Jennifer Doudna, Ph.D., using next-generation CRISPR genome-editing technology to develop “off-the-shelf” (allogeneic) CAR therapies for hard-to-treat blood cancers.

Blood Cancer Research Poised for Another ‘Banner Year’ in 2024

More than 25,000 medical professionals from across the world came together in December to discuss the latest blood cancer developments during the annual meeting of the American Society of Hematology (ASH). This annual event gives us the opportunity to think about what advances are on the horizon as LLS works to strengthen cures, care and quality of life for people with blood cancer and their families.   

Development of a novel BCL2L1 armored CAR T-cell and a tumor-immune interactome in multiple myeloma

Novel immune approaches have revolutionized the treatment paradigms in multiple myeloma (MM) with deep responses seen in heavily pretreated patients. However responses are largely not durable with significant gaps remaining in our understanding of the mechanisms mediating the immune escape to to CAR T cells and T cell engagers.

Meet the Researcher: Malathy Shanmugam, PhD, MS

Research Highlight: Changing the Landscape of Treatment for Multiple Myeloma (Part 1)

FDA Approval: New Treatment Indication for Multiple Myeloma Drug

Global Partnership to Fund Groundbreaking Research in Treatment of Multiple Myeloma

Multiple Myeloma (MM): Diagnosis, Treatment and Side Effect Management

Dissect the function of histone demethylase KDM5 on overcoming drug resistance toward immunotherapy in multiple myeloma

We identified that KDM5 can regulate important transcription factors in multiple myeloma (MM) and regulate the bone marrow (BM) microenvironment in providing protection toward MM, which also reduces anti-MM immunity. Thus, our study will utilize our novel potent and selective KDM5 inhibitor to fully dissect the interactions between MM cells, the BM microenvironment and the immune system in cellular and animal models to establish important mechanistic insights into MM.

Early Detection and Intervention in Smoldering Multiple Myeloma: population-based screening and treatment; Edit-SMM

We build on the success from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study, where over 80,000 consented to a nationwide screening for MM precursors. A unique cohort of patients with SMM diagnosed in iStopMM will be followed by clinical evaluation, linking to central health data registries, using novel biomarkers, and in-depth genetics. With precision early treatment we aim to induce a paradigm shift leading to improved quality of life and potentially a cure for MM.

Improving outcomes of multiple myeloma using TGF-beta resistant BCMA-targeted CAR T cells

Immunotherapy using chimeric antigen receptor (CAR) T cells, or CARTs for short, holds great promise for improving outcomes and survival of patients with relapsed and/or refractory multiple myeloma (RRMM). Next-generation “armored” CARTs that can overcome transforming growth factor beta (TGF-beta) dependent immune suppression in the tumor microenvironment may provide deeper and more durable disease control than the TGF-beta sensitive CART products currently in clinical use.

Highlights from ASCO 2021

Ixazomib

Ixazomib is FDA approved in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Honoring Blood Cancer Survivors

Throughout June, in commemoration of #NationalCancerSurvivorMonth, we at LLS have been highlighting the resilience and achievements of blood cancer survivors. I’ve treated so many incredible young survivors in my years as a pediatric hematologist oncologist, and all of them hold a special place in my heart. 

FDA Approves Two New Treatments for Heavily Pretreated Multiple Myeloma

Latest FDA Approval Demonstrates Improved Response Times in Multiple Myeloma

FDA Approves Targeted Therapy for Patients with Newly Diagnosed Multiple Myeloma

Melphalan hydrochloride

U.S. Food and Drug Administration (FDA) has granted approval of EVOMELA for use in two indications:

1. Use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with multiple myeloma (MM)
2. For the palliative treatment of patients with MM for whom oral therapy is not appropriate.

This is the first product to be FDA-approved for the high-dose conditioning indication in MM.

Talquetamab-tgvs

Talquetamab-tgvs is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Elranatamab-bcmm

Elranatamab-bcmm is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Ciltacabtagene autoleucel

Ciltacabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.